Home
Drugs
Targets
Pathways
Ontologies
Cyp450s
Adv.search
Help/FAQ

Drug-Target Interaction

Drug

show drug details
PubChem ID:5196
Structure:
Synonyms:
363634_ALDRICH
4-03-00-00177 (Beilstein Handbook Reference)
563-41-7
563-41-7 (mono-hydrochloride)
57-56-7
AC1L1JT9
AG-G-03246
AIDS-212516
AIDS212516
Aminoharnstoff
Aminomocovina
Aminomocovina [Czech]
Aminourea
BRN 0506319
C010059
C02077
Carbamic acid, hydrazide
Carbamidsaeurehydrazid
Carbamoylhydrazine
Carbamylhydrazine
carbamylhydrazine monohydrochloride
carbamylhydrazine, 14C-labeled
Carbazamide
CCG-205173
CHEBI:28306
CHEMBL903
EINECS 200-339-6
Hydrazine, carbamoyl-
Hydrazinecarboxamide
I05-0080
Lopac-S-2201
Lopac0_001096
LS-144844
NCGC00015934-01
NCGC00015934-02
NCGC00015934-03
NCGC00015934-04
NCGC00015934-05
NCGC00091589-02
Semicarbazide
Semicarbazide (SEM)
Semicarbazide hydrochloride
Semikarbazid
Semikarbazid [Czech]
Urea, amino-

Target

show target details
Uniprot ID:A4TB13_MYCGI
Synonyms:
Amine oxidase (Copper-containing)
EC-Numbers:1.4.3.6
Organism:Mycobacterium flavescens (strain ATCC 700033 / PYR-GCK
Mycobacterium gilvum
strain PYR-GCK
PDB IDs:-

Binding Affinities:

Ki: Kd:Ic 50:Ec50/Ic50:
----

References:

17977742
Reduction of fat deposition by combined inhibition of monoamine oxidases and semicarbazide-sensitive amine oxidases in obese Zucker rats.. C Carpéné; Z Iffiú-Soltesz; S Bour; D Prévot; P Valet (2007) Pharmacological research : the official journal of the Italian Pharmacological Society display abstract
Semicarbazide-sensitive amine oxidase (SSAO) and monoamine oxidases (MAO) are highly expressed in adipocytes and generate hydrogen peroxide when activated. Consequently, high concentrations of MAO- or SSAO-substrates acutely stimulate glucose transport and inhibit lipolysis in isolated adipocytes in a hydrogen peroxide-dependent manner. Chronic treatments with MAO and SSAO substrates also increase in vitro adipogenesis and in vivo glucose utilization and fat deposition in diabetic rodents. To further investigate the interplay between amine oxidases, energy balance and fat deposition, prolonged MAO and/or SSAO blockade was performed in obese rats. Pargyline (P, MAO inhibitor), semicarbazide (S, SSAO inhibitor), alone or in combination (P+S), were daily i.p. administered for 3-5 weeks to obese Zucker rats at doses ranging from 20 to 300 micromol/kg. P+S treatments abolished MAO and SSAO activities in any tested tissue. P and S led to a 12-17% reduction of food intake when given in combination but were inactive when given separately. Despite a similar body weight gain reduction in P+S-treated and pair-fed rats, the mitigation of fat deposition was greater in rats receiving both inhibitors. Adipocytes from P+S-treated rats responded as control to insulin but exhibited impaired responses to tyramine, benzylamine or methylamine plus vanadate when considering glucose transport activation or lipolysis inhibition. Although our results did not directly demonstrate that amines are able to spontaneously produce in vivo the insulin-like effects described in vitro, we propose that P+S-induced reduction of fat deposition results from decreased food intake and from impaired MAO- and SSAO-dependent lipogenic and antilipolytic actions of endogenous or alimentary amines.